Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BionetROCO:1784 -1.86%80 EV-to-EBIT is 111.52 as of Sep. 21, 2026, which is 175% above its 10-year median of 40.60. GuruFocus rates ROCO:1784 with a GF Score™ of 80/100 and a GF Value™ of NT$82.71 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, Bionet ranks worse than 93.75% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bionet's Enterprise Value is NT$2,666 Mil.
Bionet's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$24 Mil. Therefore, Bionet's EV-to-EBIT for today is 111.52.
The historical rank and industry rank for Bionet's EV-to-EBIT or its related term are showing as below:
ROCO:1784'
s EV-to-EBIT Range Over the Past 10 Years
Min: -406.57 Med: 40.6 Max: 470.08
Current: 111.52
During the past 13 years, the highest EV-to-EBIT of Bionet was 470.08. The lowest was -406.57. And the median was 40.60.
ROCO:1784's EV-to-EBIT is ranked worse than 93.75% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 25.875
vs ROCO:1784: 111.52
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bionet's Enterprise Value for the quarter that ended in Jun. 2026 was NT$3,050 Mil.
Bionet's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionet EV-to-EBIT Related Terms
Bionet EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bionet's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1784 vs TMO, DHR, NTRA: EV-to-EBIT Comparison
For the Diagnostics & Research subindustry, Bionet's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionet EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bionet's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bionet's EV-to-EBIT falls into.
Bionet's current Enterprise Value is NT$2,666 Mil.
Bionet's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionet (ROCO:1784) has a EV-to-EBIT of 111.52 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bionet and its competitors. This is 175% above median its historical median of 40.60. According to the industry distribution chart, Bionet ranks #105 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 93.7%.
Is Bionet's EV-to-EBIT too high?
Bionet's current EV-to-EBIT of 111.52 is 175% above median its 10-year median of 40.60. The Medical Diagnostics & Research industry median EV-to-EBIT is 25.88. Bionet's value of 111.52 is 331% above this industry median. Based on the distribution chart, Bionet ranks #105 out of 112 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Bionet has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionet's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bionet ranks #105 out of 112 companies for EV-to-EBIT. This places Bionet in the lower half of its industry. The industry median EV-to-EBIT is 25.88. Bionet's value of 111.52 is 331% above this benchmark. While the company's 10-year median is 40.60 vs. the industry median of 25.88, Bionet has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 25.88, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionet's current EV-to-EBIT of 111.52 is 331% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bionet and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 25.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionet's current EV-to-EBIT is 111.52, which is 175% above median its own 10-year median of 40.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet stock overvalued right now?
Based on GuruFocus' analysis, Bionet (ROCO:1784) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$82.71, compared to a current price of NT$58.00 — trading 29.9% below its estimated fair value. The current EV-to-EBIT is 111.52, which is 175% above median its 10-year median of 40.60 and 331% above the Medical Diagnostics & Research industry median of 25.88. Bionet's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bionet (ROCO:1784), the current EV-to-EBIT is 111.52 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionet (ROCO:1784) Overvalued in 2026?
Based on GuruFocus' analysis, Bionet stock appears to be undervalued.
The current stock price of NT$58.00 is trading 29.9% below its estimated GF Value™ of NT$82.71.
GuruFocus considers Bionet to be Significantly Undervalued.
Key valuation signals for ROCO:1784:
EV-to-EBIT: 111.52 (175% above median its 10-year median of 40.60)
GF Value™: NT$82.71 vs. price of NT$58.00 (29.9% below fair value)
Industry Position: 331% above the Medical Diagnostics & Research median (#105 of 112)
No single metric tells the full story. See the ROCO:1784 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionet Corp provides blood bank and stem cell services. It is a preservation center for stem cells such as Umbilical Cord Mesenchymal Stem Cells and Dental Pulp Stem Cell Stem.
80GF Score
Get the complete analysis for ROCO:1784
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1784 has been successfully added to your 
